In a remarkable decision posted earlier this month, INESSS stands alone in failing to recognize the therapeutic value of XPOVIO. This despite Health Canada approval, a positive CADTH decision, Quebec clinician and patient support and positive funding recommendations from such organizations as Australia’s PBAC and most recently Britain’s NICE.
This negative recommendation by INESSS raises many concerning questions but most importantly isolates the Quebec patients and treating community on a very distinct and unique island. We see, yet again, the ‘postal code lottery” of access at play in our country. We have to find better, more consistent solutions for Canadian patients.
Read on our LinkedIn and we refer you to FORUS press release online link in English dated April 24th for additional information.